相关实验视频

Updated: Jun 24, 2025

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

法国青少年的人类乳头瘤病毒 (HPV) 疫苗接种覆盖率:一项索赔数据研究

G de Pouvourville¹, E Guyot², G Farge³

¹ESSEC Business School, 3 avenue Bernard Hirsch, CS 50105 Cergy, 95021 Cergy-Pontoise Cedex, France.

|June 9, 2024

概括

人类乳头瘤病毒 (HPV) 疫苗接种覆盖率在法国女孩中增加,但仍然不足. 在男孩中开始接种疫苗是一个有希望的开始,强调需要持续监测和改进策略.

科学领域:

公共卫生公共卫生
疫苗学疫苗学疫苗学
流行病学流行病学

背景情况:

法国2021-2030年癌症控制战略的目标是80%的人类乳头瘤病毒 (HPV) 疫苗接种覆盖率.
自2021年以来,建议男孩 (11-14岁) 接种HPV疫苗,未接种疫苗的青少年 (19岁以下) 接种疫苗.

研究的目的:

使用索赔数据,监测法国人口中HPV疫苗接种覆盖率 (VCR) 的演变.
评估青少年的HPV疫苗接种率.
为了跟踪与年龄和性别相关的累积疫苗接种率.

主要方法:

2017年至2022年使用法国索赔数据分析年度HPV VCR.
部分 (≥1剂量) 和全 (2-3剂量在18个月内) 疫苗接种方案的定义.
估计11-19岁青少年的年度启动率和累计VCR.

主要成果:

在2017-2022年期间,超过177万名女性和592,167名男性启动了HPV疫苗接种.
开始主要发生在11-14岁之间 (67.3%的女性,62.4%的男性).
15岁女孩的累计VCR (部分) 从2017年的28.1%上升到2022年的50.9%;16岁 (全) 从15.5%上升到33.8%.

结论:

女孩的HPV疫苗接种率有所增加,但仍低于目标.
男孩最初接种HPV疫苗的情况令人鼓舞,这表明未来增长的潜力.
持续监测至关重要,尤其是在社区药剂师扩大疫苗接种能力的情况下.

关键词:

索赔数据库索赔数据库完全接种疫苗的情况.人类乳头瘤病毒人类乳头瘤病毒部分疫苗接种部分疫苗接种接种疫苗的覆盖率是多少

更多相关视频

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

相关概念视频

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Vaccinations

Vaccinations

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cancer Prevention

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...